PD-L1 expression by immunohistochemistry in salivary duct carcinoma.
Aged
B7-H1 Antigen
/ antagonists & inhibitors
Carcinoma
/ diagnosis
Female
Humans
Immunohistochemistry
Immunotherapy
Kaplan-Meier Estimate
Male
Middle Aged
Prognosis
Programmed Cell Death 1 Receptor
/ antagonists & inhibitors
Retrospective Studies
Salivary Ducts
/ metabolism
Salivary Gland Neoplasms
/ diagnosis
Checkpoint inhibitors
Immunotherapy
PD-1
PD-L1
Salivary duct carcinoma
Journal
Annals of diagnostic pathology
ISSN: 1532-8198
Titre abrégé: Ann Diagn Pathol
Pays: United States
ID NLM: 9800503
Informations de publication
Date de publication:
Jun 2019
Jun 2019
Historique:
received:
08
01
2019
revised:
20
03
2019
accepted:
02
04
2019
pubmed:
13
4
2019
medline:
7
1
2020
entrez:
13
4
2019
Statut:
ppublish
Résumé
Immune checkpoint inhibitors play an increasing role in oncologic care. PD-L1 expression is associated with survival and predicts response to PD-1 or PD-L1 inhibitors in a variety of tumors. Our aim is to evaluate the frequency and prognostic significance of PD-L1 expression in salivary duct carcinoma. We retrospectively evaluated the expression of PD-L1 by two different antibodies (PD-L1 28-8 and PD-L1 22C3) in salivary duct carcinomas. PD-L1 expression in at least 1% of tumor cells was considered immunoreactive. Kaplan-Meier analysis was performed to determine the impact of PD-L1 expression on survival; differences between survival curves were assessed by the chi-square test, and pairwise comparisons of factors were assessed with the log-rank test. A total of 113 patients' specimens were evaluated. Seventy-six (76%) of the patients were male. Mean age at time of presentation was 61.2 (SD = 12.4) years. PD-L1 expression was found in 26% of the samples. Median follow-up time was 36.6 months (range = 1.4-249 months). Overall survival at 3, 5 and 10 years were 52.6%, 37.9% and 25.6%, respectively. There was no statistical difference in survival between patients with PD-L1-immunoreactive tumors and those without, regardless of which antibody was used (chi In our analysis, PD-L1 expression occurred in a small proportion of salivary duct carcinomas, usually at low levels, and did not correlate with survival. Its predictive value and utility in selecting patients with salivary duct carcinoma who might benefit from PD-1/PD-L1 inhibitors warrants further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
Immune checkpoint inhibitors play an increasing role in oncologic care. PD-L1 expression is associated with survival and predicts response to PD-1 or PD-L1 inhibitors in a variety of tumors. Our aim is to evaluate the frequency and prognostic significance of PD-L1 expression in salivary duct carcinoma.
DESIGN
METHODS
We retrospectively evaluated the expression of PD-L1 by two different antibodies (PD-L1 28-8 and PD-L1 22C3) in salivary duct carcinomas. PD-L1 expression in at least 1% of tumor cells was considered immunoreactive. Kaplan-Meier analysis was performed to determine the impact of PD-L1 expression on survival; differences between survival curves were assessed by the chi-square test, and pairwise comparisons of factors were assessed with the log-rank test.
RESULTS
RESULTS
A total of 113 patients' specimens were evaluated. Seventy-six (76%) of the patients were male. Mean age at time of presentation was 61.2 (SD = 12.4) years. PD-L1 expression was found in 26% of the samples. Median follow-up time was 36.6 months (range = 1.4-249 months). Overall survival at 3, 5 and 10 years were 52.6%, 37.9% and 25.6%, respectively. There was no statistical difference in survival between patients with PD-L1-immunoreactive tumors and those without, regardless of which antibody was used (chi
CONCLUSION
CONCLUSIONS
In our analysis, PD-L1 expression occurred in a small proportion of salivary duct carcinomas, usually at low levels, and did not correlate with survival. Its predictive value and utility in selecting patients with salivary duct carcinoma who might benefit from PD-1/PD-L1 inhibitors warrants further investigation.
Identifiants
pubmed: 30978575
pii: S1092-9134(19)30014-0
doi: 10.1016/j.anndiagpath.2019.04.001
pmc: PMC6599643
mid: NIHMS1526707
pii:
doi:
Substances chimiques
B7-H1 Antigen
0
CD274 protein, human
0
PDCD1 protein, human
0
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-52Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2019 Elsevier Inc. All rights reserved.
Références
Eur J Cancer. 2019 Mar;110:62-70
pubmed: 30771738
Head Neck Pathol. 2013 Jul;7 Suppl 1:S48-58
pubmed: 23821208
Hum Pathol. 2018 Dec;82:131-139
pubmed: 30075156
Head Neck. 2016 Apr;38 Suppl 1:E820-6
pubmed: 25916947
Acta Histochem. 2006;108(1):19-24
pubmed: 16530813
J Clin Oncol. 2016 Nov 10;34(32):3838-3845
pubmed: 27646946
Lancet Oncol. 2016 Jul;17(7):956-965
pubmed: 27247226
Am J Surg Pathol. 2003 Aug;27(8):1070-9
pubmed: 12883239
Cancer. 2010 Apr 1;116(7):1757-66
pubmed: 20143437
Am J Clin Pathol. 2004 Aug;122(2):222-31
pubmed: 15323139
Am J Clin Oncol. 2018 Nov;41(11):1083-1088
pubmed: 29462123
Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12293-7
pubmed: 12218188
Head Neck Pathol. 2019 Dec;13(4):529-534
pubmed: 30390196
Hum Pathol. 2000 Feb;31(2):208-13
pubmed: 10685635
Breast Cancer Res Treat. 2014 Jul;146(1):15-24
pubmed: 24842267
Clin Cancer Res. 2007 Apr 1;13(7):2151-7
pubmed: 17404099
Cancer. 2005 Jun 15;103(12):2526-33
pubmed: 15900577
Head Neck. 2014 May;36(5):694-701
pubmed: 23606370
J Clin Diagn Res. 2015 Feb;9(2):ZE04-8
pubmed: 25859537
J Surg Oncol. 2016 Jul;114(1):36-43
pubmed: 27111278
J Oral Pathol Med. 2018 Aug;47(7):683-690
pubmed: 29719073
J Clin Oncol. 2019 Jan 10;37(2):125-134
pubmed: 30452336